American journal of ophthalmology · 2026
Association Between Retinal Vein Occlusion and Epiretinal Membrane Development.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almosa Abdulkader, Alshaikhsalama Ahmed M, Abdi Ahmed, Alsoudi Amer F, Yuan Melissa, Loya Asad, Rahimy Ehsan, Mahmoud Tamer H
Аннотация
PURPOSE: To evaluate the temporal association between retinal vein occlusion (RVO) and the development of epiretinal membrane (ERM) including subsequent ERM peel.
DESIGN: Retrospective cohort study.
PARTICIPANTS: After propensity score matching (PSM) and applying inclusion/exclusion criteria, 19,172 patients with branch retinal vein occlusion (BRVO) and 14,974 with central retinal vein occlusion (CRVO) were compared with matched controls.
METHODS: Data was extracted using a national clinical database. Patients with BRVO or CRVO were compared with individuals without RVO (control) for the development of main outcomes measures. Secondary analyses examined RVO cohorts with anti-VEGF injections: BRVO-T (anti-VEGF-treated) and CRVO-T versus their respective untreated counterparts.
MAIN OUTCOME MEASURES: Relative risk (RR) of incident ERM formation and ERM peel at multiple time points from 3 months to 5 years.
RESULTS: During the 5-year study period, BRVO and CRVO cohorts had the highest risk for ERM formation at 3 months compared with their respective controls (BRVO: RR = 4.54; CRVO: RR = 4.90; P < .0001). The risk of ERM peel was greatest at one year for BRVO (RR, 3.83; P < .0001) and 3 years for CRVO (RR, 3.91; P < .0001). In the secondary analysis, anti-VEGF treatment was associated with higher ERM rates at 3 months in BRVO-T (RR, 5.60; P < .0001) and CRVO-T (RR, 6.80; P < .0001) cohorts. The incidence of ERM peel peaked later in treated eyes at 5 years (BRVO-T: RR, 3.30; P = .0004; CRVO-T: RR, 2.60; P = .0075) compared with untreated eyes.
CONCLUSIONS: ERM formation typically occurs during the first 3 months following RVO, while surgical intervention peaks later, as early as one year in untreated eyes, and 5 years in eyes treated with anti-VEGF agents. Treated patients also exhibited an elevated risk for ERM development, which could be influenced by differences in baseline disease severity rather than a clear treatment effect.
DESIGN: Retrospective cohort study.
PARTICIPANTS: After propensity score matching (PSM) and applying inclusion/exclusion criteria, 19,172 patients with branch retinal vein occlusion (BRVO) and 14,974 with central retinal vein occlusion (CRVO) were compared with matched controls.
METHODS: Data was extracted using a national clinical database. Patients with BRVO or CRVO were compared with individuals without RVO (control) for the development of main outcomes measures. Secondary analyses examined RVO cohorts with anti-VEGF injections: BRVO-T (anti-VEGF-treated) and CRVO-T versus their respective untreated counterparts.
MAIN OUTCOME MEASURES: Relative risk (RR) of incident ERM formation and ERM peel at multiple time points from 3 months to 5 years.
RESULTS: During the 5-year study period, BRVO and CRVO cohorts had the highest risk for ERM formation at 3 months compared with their respective controls (BRVO: RR = 4.54; CRVO: RR = 4.90; P < .0001). The risk of ERM peel was greatest at one year for BRVO (RR, 3.83; P < .0001) and 3 years for CRVO (RR, 3.91; P < .0001). In the secondary analysis, anti-VEGF treatment was associated with higher ERM rates at 3 months in BRVO-T (RR, 5.60; P < .0001) and CRVO-T (RR, 6.80; P < .0001) cohorts. The incidence of ERM peel peaked later in treated eyes at 5 years (BRVO-T: RR, 3.30; P = .0004; CRVO-T: RR, 2.60; P = .0075) compared with untreated eyes.
CONCLUSIONS: ERM formation typically occurs during the first 3 months following RVO, while surgical intervention peaks later, as early as one year in untreated eyes, and 5 years in eyes treated with anti-VEGF agents. Treated patients also exhibited an elevated risk for ERM development, which could be influenced by differences in baseline disease severity rather than a clear treatment effect.